<DOC>
	<DOCNO>NCT00984763</DOCNO>
	<brief_summary>Malaria parasite , infection kill 2 million people year . It major problem live endemic area traveller . There great need safe effective malaria vaccine . The purpose study examine new vaccine design provide immunity blood stage malaria parasite 's lifecycle . The vaccine consist AMA1-C1 mixture two recombinant synthetic AMA1 proteins two Plasmodium falciparum strain , Alhydrogel® aluminium-based adjuvant CPG 7909 - oligodeoxynucleotide , enhance immune response . This study enable investigator assess : 1 . The ability growth inhibition assay predict effectiveness malaria vaccine . 2 . The safety vaccine healthy volunteer 3 . The response human immune system vaccine</brief_summary>
	<brief_title>A Study Assess Safety , Immunogenicity Parasite Growth Inhibition Asexual Blood Stage Vaccine P. Falciparum Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Subject willing able give inform consent participation study Healthy , non pregnant adult age 18 50 year Resident near Oxford duration challenge study Seropositive CMV EBV Female subject child bear potential must willing ensure practice effective contraception study Males must willing use barrier contraception day first vaccination onwards 3 month second vaccination Able ( Investigator 's opinion ) willing comply study requirement Willing allow General Practitioner consultant , appropriate , notified participation study Agreement permanently refrain blood donation . Any deviation normal range biochemistry haematology blood test urine analysis define Appendix B Female patient/subject pregnant , lactate plan pregnancy course study Healthy volunteer participate another research study involve investigational product past 12 week Subjects previously receive investigational malaria vaccine History malaria chemoprophylaxis chloroquine within 5 month prior plan challenge , Lariam within 6 week prior challenge , Riamet® within 2 week prior challenge Travel malaria endemic area within previous 6 month Planned travel malarious area study period Any history malaria Contraindication antimalarial drug ( Riamet® chloroquine ) concomitant use drug know cause QTinterval prolongation , ( e.g . macrolides , quinolones , amiodarone etc ) An estimate ten year risk fatal cardiovascular disease ≥5 % , estimate Systematic Coronary Risk Evaluation ( SCORE ) system ( Conroy 2003 ) Family history sudden cardiac death History cardiac arrhythmia prolong QT syndrome Any history severe allergic reaction anaphylaxis History know allergy nickel Any confirm suspected immunosuppressive immunodeficient state , include HIV infection ; asplenia ; recurrent severe infection chronic ( 14 day ) immunosuppressant medication within past 6 month History evidence preexist autoimmune antibody mediate disease laboratory evidence possible autoimmune disease ( define antidsDNA ≥ 25 IU/mL ) Seropositive hepatitis B surface antigen ( HBsAg ) antibodies hepatitis C virus Any ongoing chronic illness require hospital specialist supervision Administration immunoglobulins and/or blood product within three month precede plan administration vaccine candidate History current intravenous drug abuse Suspected know current alcohol abuse define alcohol intake great 42 unit every week Any significant disease disorder , opinion Investigator , may either put subject risk participation study , may influence result study , subject 's ability participate study . Investigator assessment lack willingness participate comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Vaccine</keyword>
</DOC>